Repository logo
 

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population.

Simple item page
cam.depositDate2022-04-20
cam.issuedOnline2022-04-24
cam.orpheus.counter1
cam.orpheus.successWed May 25 11:13:41 BST 2022 - This item is covered by RRS with an embargo. The item is now published and embargo has been lifted.*
dc.contributor.authorBarr, Chloe E
dc.contributor.authorFunston, Garth
dc.contributor.authorJeevan, David
dc.contributor.authorSundar, Sudha
dc.contributor.authorMounce, Luke TA
dc.contributor.authorCrosbie, Emma J
dc.contributor.orcidFunston, Garth [0000-0002-4156-6401]
dc.contributor.orcidCrosbie, Emma J [0000-0003-0284-8630]
dc.date.accessioned2022-04-21T23:30:22Z
dc.date.available2022-04-21T23:30:22Z
dc.date.issued2022-04-24
dc.date.updated2022-04-20T22:10:49Z
dc.description.abstractHuman epididymis 4 (HE4) is a promising ovarian cancer biomarker, but it has not been evaluated in primary care. In this prospective observational study, we investigated the diagnostic accuracy of HE4 alone and in combination with CA125 for the detection of ovarian cancer in symptomatic women attending primary care. General practitioner (GP)-requested CA125 samples were tested for HE4 at a large teaching hospital in Manchester, and cancer outcomes were tracked for 12 months. We found a low incidence of ovarian cancer in primary care; thus, the cohort was enriched with pre-surgical samples from 81 ovarian cancer patients. The Risk of Ovarian Malignancy Algorithm (ROMA) was calculated using age (</>51) as a surrogate for menopause. Conventional diagnostic accuracy metrics were determined. A total of 1229 patients were included; 82 had ovarian cancer. Overall, ROMA performed best (AUC-0.96 (95%CI: 0.94-0.98, p = <0.001)). In women under 50 years, the combination of CA125 and HE4 (either marker positive) was superior (sensitivity: 100% (95%CI: 81.5-100.0), specificity: 80.1% (95%CI 76.7-83.1)). In women over 50, ROMA performed best (sensitivity: 84.4% (95%CI: 73.1-92.2), specificity: 87.2% (95%CI 84.1-90)). HE4 and ROMA may improve ovarian cancer detection in primary care, particularly for women under 50 years, in whom diagnosis is challenging. Validation in a larger primary care cohort is required.
dc.description.sponsorshipLumipulse®G HE4 immunoassay kits were generously donated by Fujirebio for use in this re-search. Fujirebio played no other role in the conduct of this study, analysis of the data or the deci-sion to publish. CEB was supported through an MFT Clinical Research Fellowship and EJC through the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). This work was supported by Wellbeing of Women (Award Reference ELS701) (GF, EJC). DJ was supported by Wellbeing of Women (Award Reference RTF707).
dc.identifier.doi10.17863/CAM.83762
dc.identifier.eissn2072-6694
dc.identifier.issn2072-6694
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/336342
dc.language.isoeng
dc.publisherMDPI AG
dc.publisher.departmentDepartment of Public Health And Primary Care, The Primary Care Unit
dc.rightsAll Rights Reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.titleThe Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population.
dc.typeArticle
dcterms.dateAccepted2022-04-19
prism.publicationNameCancers (Basel)
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
pubs.licence-identifierapollo-deposit-licence-2-1
rioxxterms.typeJournal Article/Review
rioxxterms.versionAM
rioxxterms.versionofrecord10.3390/cancers14092124

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
cancers-1663641_clean.docx
Size:
529.76 KB
Format:
Unknown data format
Description:
Accepted version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download

Collections

Cambridge University Research Outputs